Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IOV 3001

Next Previous
Drug Profile

IOV 3001

Alternative Names: IOV-3001; Next generation IL-2 for TIL treatment regimen - Iovance Biotherapeutics

Latest Information Update: 14 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Iovance Biotherapeutics
  • Class Antineoplastics; Immunotherapies; Recombinant proteins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 27 Feb 2025 Phase-I/II clinical trials in Cancer (Parenteral)
  • 31 May 2024 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical studies in Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology, 2024 (ASCO-2024)
  • 09 May 2024 Iovance Biotherapeutics plans to submit an IND for a phase I/II clinical trial in Cancer (for use in the TIL therapy treatment regimen) in the third quarter of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top